These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

198 related items for PubMed ID: 39007830

  • 1. Temporary omission of oral anticoagulation in atrial fibrillation patients undergoing percutaneous coronary intervention: rationale and design of the WOEST-3 randomised trial.
    Verburg A, Bor WL, Küçük IT, Henriques JPS, Vink MA, Ruifrok WT, Plomp J, Heestermans TACM, Schotborgh CE, Vlaar PJ, Magro M, Rikken SAOF, van den Broek WWA, van Mieghem CAG, Cornelis K, Rosseel L, Dujardin KS, Vandeloo B, Vandendriessche T, Ferdinande B, van 't Hof AWJ, Tijssen JGP, Limbruno U, De Caterina R, Rubboli A, Angiolillo DJ, Adriaenssens T, Dewilde W, Ten Berg JM.
    EuroIntervention; 2024 Jul 15; 20(14):e898-e904. PubMed ID: 39007830
    [Abstract] [Full Text] [Related]

  • 2. The Cost of Breaking Even: a Perspective on the Net Clinical Impact of Adding Aspirin to Antithrombotic Therapies in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention.
    Triska J, Haddadin F, Madanat L, Jabri A, Daher M, Birnbaum Y, Jneid H.
    Cardiovasc Drugs Ther; 2024 Jun 15; 38(3):605-619. PubMed ID: 35829979
    [Abstract] [Full Text] [Related]

  • 3. Design and Rationale of the RE-DUAL PCI Trial: A Prospective, Randomized, Phase 3b Study Comparing the Safety and Efficacy of Dual Antithrombotic Therapy With Dabigatran Etexilate Versus Warfarin Triple Therapy in Patients With Nonvalvular Atrial Fibrillation Who Have Undergone Percutaneous Coronary Intervention With Stenting.
    Cannon CP, Gropper S, Bhatt DL, Ellis SG, Kimura T, Lip GY, Steg PG, Ten Berg JM, Manassie J, Kreuzer J, Blatchford J, Massaro JM, Brueckmann M, Ferreiros Ripoll E, Oldgren J, Hohnloser SH, RE-DUAL PCI Steering Committee and Investigators.
    Clin Cardiol; 2016 Oct 15; 39(10):555-564. PubMed ID: 27565018
    [Abstract] [Full Text] [Related]

  • 4. Bleeding and ischaemic outcomes in patients treated with dual or triple antithrombotic therapy: systematic review and meta-analysis.
    Haller PM, Sulzgruber P, Kaufmann C, Geelhoed B, Tamargo J, Wassmann S, Schnabel RB, Westermann D, Huber K, Niessner A, Gremmel T.
    Eur Heart J Cardiovasc Pharmacother; 2019 Oct 01; 5(4):226-236. PubMed ID: 31198930
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Ticagrelor alone versus ticagrelor plus aspirin from month 1 to month 12 after percutaneous coronary intervention in patients with acute coronary syndromes (ULTIMATE-DAPT): a randomised, placebo-controlled, double-blind clinical trial.
    Ge Z, Kan J, Gao X, Raza A, Zhang JJ, Mohydin BS, Gao F, Shao Y, Wang Y, Zeng H, Li F, Khan HS, Mengal N, Cong H, Wang M, Chen L, Wei Y, Chen F, Stone GW, Chen SL, ULTIMATE-DAPT investigators.
    Lancet; 2024 May 11; 403(10439):1866-1878. PubMed ID: 38599220
    [Abstract] [Full Text] [Related]

  • 9. Triple therapy: A review of antithrombotic treatment for patients with atrial fibrillation undergoing percutaneous coronary intervention.
    Saito Y, Kobayashi Y.
    J Cardiol; 2019 Jan 11; 73(1):1-6. PubMed ID: 30293674
    [Abstract] [Full Text] [Related]

  • 10. Meta-Analysis Comparing Potent Oral P2Y12 Inhibitors versus Clopidogrel in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention.
    Casula M, Fortuni F, Ferlini M, Fabris F, Oltrona Visconti L, Leonardi S.
    Am J Cardiovasc Drugs; 2021 Mar 11; 21(2):231-240. PubMed ID: 32895853
    [Abstract] [Full Text] [Related]

  • 11. Risk of Stroke vs. Intracerebral Hemorrhage in Patients with Non-Valvular Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis of Randomized Controlled Trials Comparing Dual vs. Triple Antithrombotic Therapy.
    Desai A, Escamilla-Ocanas C, Dilip D, Saber H, Damani R.
    J Stroke Cerebrovasc Dis; 2021 Apr 11; 30(4):105654. PubMed ID: 33578352
    [Abstract] [Full Text] [Related]

  • 12. Oral anticoagulation and antiplatelets in atrial fibrillation patients after myocardial infarction and coronary intervention.
    Lamberts M, Gislason GH, Olesen JB, Kristensen SL, Schjerning Olsen AM, Mikkelsen A, Christensen CB, Lip GY, Køber L, Torp-Pedersen C, Hansen ML.
    J Am Coll Cardiol; 2013 Sep 10; 62(11):981-9. PubMed ID: 23747760
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Antithrombotic Therapy in Patients With Atrial Fibrillation and Acute Coronary Syndrome Treated Medically or With Percutaneous Coronary Intervention or Undergoing Elective Percutaneous Coronary Intervention: Insights From the AUGUSTUS Trial.
    Windecker S, Lopes RD, Massaro T, Jones-Burton C, Granger CB, Aronson R, Heizer G, Goodman SG, Darius H, Jones WS, Aschermann M, Brieger D, Cura F, Engstrøm T, Fridrich V, Halvorsen S, Huber K, Kang HJ, Leiva-Pons JL, Lewis BS, Malaga G, Meneveau N, Merkely B, Milicic D, Morais J, Potpara TS, Raev D, Sabaté M, de Waha-Thiele S, Welsh RC, Xavier D, Mehran R, Alexander JH, AUGUSTUS Investigators.
    Circulation; 2019 Dec 03; 140(23):1921-1932. PubMed ID: 31557056
    [Abstract] [Full Text] [Related]

  • 16. Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation.
    Cannon CP, Bhatt DL, Oldgren J, Lip GYH, Ellis SG, Kimura T, Maeng M, Merkely B, Zeymer U, Gropper S, Nordaby M, Kleine E, Harper R, Manassie J, Januzzi JL, Ten Berg JM, Steg PG, Hohnloser SH, RE-DUAL PCI Steering Committee and Investigators.
    N Engl J Med; 2017 Oct 19; 377(16):1513-1524. PubMed ID: 28844193
    [Abstract] [Full Text] [Related]

  • 17. Antithrombotic therapy in patients with non-valvular atrial fibrillation undergoing percutaneous coronary intervention: should we change our practice after the PIONEER AF-PCI and RE-DUAL PCI trials?
    Duerschmied D, Brachmann J, Darius H, Frey N, Katus HA, Rottbauer W, Schäfer A, Thiele H, Bode C, Zeymer U.
    Clin Res Cardiol; 2018 Jul 19; 107(7):533-538. PubMed ID: 29679144
    [Abstract] [Full Text] [Related]

  • 18. Dual versus triple antithrombotic therapy after percutaneous coronary intervention: the prospective multicentre WOEST 2 Study.
    Bor WL, de Veer AJW, Olie RH, Rikken SAOF, Chan Pin Yin DRPP, Herrman JPR, Vrolix M, Meuwissen M, Vandendriessche T, van Mieghem C, Magro M, Bennaghmouch N, Hermanides R, Adriaenssens T, Dewilde WJM, Ten Berg JM.
    EuroIntervention; 2022 Jul 22; 18(4):e303-e313. PubMed ID: 35370126
    [Abstract] [Full Text] [Related]

  • 19. The role of triple antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention.
    Fanaroff AC, Lopes RD.
    Prog Cardiovasc Dis; 2021 Jul 22; 69():11-17. PubMed ID: 34883097
    [Abstract] [Full Text] [Related]

  • 20. Antiplatelet Therapy in Patients Requiring Oral Anticoagulation and Undergoing Percutaneous Coronary Intervention.
    Manzi L, Florimonte D, Forzano I, Buongiorno F, Sperandeo L, Castiello DS, Paolillo R, Giugliano G, Giacoppo D, Sciahbasi A, Cirillo P, Esposito G, Gargiulo G.
    Interv Cardiol Clin; 2024 Oct 22; 13(4):527-541. PubMed ID: 39245552
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.